Corticosteroid use for diabetic macular edema: Old fad or new trend?

Current Diabetes Reports

Volumn 12, Issue 4, 2012, Pages 364-375

  Stewart, Michael W ^a  

^a MAYO CLINIC   (United States)

Author keywords

Corticosteroids; Dexamethasone; Diabetes; Diabetic retinopathy; Fluocinolone; Intravitreal injections; Macular edema; Triamcinolone

Indexed keywords

ACETYLSALICYLIC ACID; ANTIBIOTIC AGENT; AUROCORT; BEVACIZUMAB; CORTICOSTEROID; DEXAMETHASONE; FLUOCINOLONE; FLUOCINOLONE ACETONIDE; KENACORT 40; PLACEBO; RANIBIZUMAB; STEROID; TRIAMCINOLONE; TRIAMCINOLONE ACETONIDE; TRIESSENCE; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VISAGEN;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; BACTERIAL INFECTION; BRAIN EDEMA; CLINICAL EFFECTIVENESS; DIABETIC MACULAR EDEMA; DOSE RESPONSE; DRUG COST; DRUG DELIVERY SYSTEM; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG PENETRATION; DRUG POTENCY; DRUG SAFETY; DRUG SOLUBILITY; DRUG USE; ENDOPHTHALMITIS; HUMAN; HYPOXIA; INTRAOCULAR PRESSURE; IRIS DISEASE; LASER COAGULATION; MOLECULAR PATHOLOGY; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; RETINA DISEASE; RETINA MACULA AGE RELATED DEGENERATION; RHEUMATOID ARTHRITIS; SIDE EFFECT; SUSTAINED DRUG RELEASE; TREATMENT PLANNING; TREND STUDY; UNSPECIFIED SIDE EFFECT; UVEITIS; VISUAL ACUITY;

ANTI-INFLAMMATORY AGENTS; DEXAMETHASONE; DIABETIC RETINOPATHY; DRUG ADMINISTRATION SCHEDULE; DRUG IMPLANTS; FEMALE; FLUOCINOLONE ACETONIDE; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; TRIAMCINOLONE; VISUAL ACUITY;

EID: 84865595074     PISSN: 15344827     EISSN: 15390829     Source Type: Journal    
DOI: 10.1007/s11892-012-0281-8     Document Type: Article

References (133)

1. Klein R, Klein BE. Vision disorders. In Harris MWH,ed. Diabetes in America. Bethesda, MD: NIH-NIDDK Publication No. 95-1468,1995:293-338.
2. Klein R, Klein BE, Moss SE. The Wisconsin Epidemiological Study of Diabetic Retinopathy: A review. Diabetes Metab Rev. 1989;5(7):559-70. (Pubitemid 19272666)
3. DCCT. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993;329 (14):977-86.
4. UKPDR (UK Prospective Diabetes Study Group). Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317 (7160):703-13.
5. Curtis TM, Gardiner TA, Stitt AW. Microvascular lesions of diabetic retinopathy: Clues towards understanding pathogenesis? Eye. 2009;23:1496-508.
6. Caldwell RB, Bartoli M, Behzadian MA, et al. Vascular endothelial growth factor and diabetic retinopathy: Pathyphysiological mechanisms and treatment perspectives. Diab/Metab Res Rev. 2003;19:442-55. (Pubitemid 37536961)
7. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87 (1):4-14.
8. Klein R, Klein BE, Moss SE. Visual impairment in diabetes. Ophthalmology. 1984;91:1-9. (Pubitemid 14184710)
9. Yau J, Rogers S, Kawasaki R, et al. Global Prevalence and major risk factors of Diabetic Retinopathy. Diabetes Care. 2012;35:556-64.
10. Frank RN. Diabetic retinopathy. N Engl J Med. 2004;350:48-58. (Pubitemid 38032183)
11. Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BE. The Wisconsin Epidemiologic Study of Diabetic Retinopathy XXIII: The twenty-five-year incidence of macular edema in persons with type 1 diabetes. Ophthalmology. 2009;116:497-503.
12. Shea AM, Curtis, Hammill BG, et al. Resource use and costs associated with diabetic macular edema in elderly persons. Arch Ophthalmol. 2008;126(12):1748-54.
13. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol. 1985;103:1796-806.
14. McDonald HR, Schatz H. Grid photocoagulation for diffuse macular edema. Retina. 1985;5:65-72. (Pubitemid 15004310)
15. Uhlmann K, Kovacs, Boettcher Y, et al. Genetics of diabetic retinopathy. Exp Clin Endocrinol Diab. 2006;114:275-94. (Pubitemid 44166174)
16. Hanis CL, Hallman D. Genetics of diabetic retinopathy. Curr Diab Rep. 2006;6:155-61.
17. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414(6865):813-20. (Pubitemid 34000785)
18. Nguyen QD, Shah SM, Van Anden E, et al. Supplemental oxygen improves diabetic macular edema: A pilot study. Invest Ophthalmol Vis Sci. 2004;45:617-24. (Pubitemid 38140522)
19. Ozaki H, Hayashi H, Vinores SA, et al. Intravitreal sustained release of VEGF causes retinal neovascularization in rabbits and breakdown of the blood-retinal barrier in rabbits and primates. Exp Eye Res. 1997;64:505-17. (Pubitemid 27321334)
20. Aiello LP. Angiogenic pathways in diabetic retinopathy. N Engl J Med. 2005;353:839-41. (Pubitemid 41215495)
21. Gardner TW, Antonetti DA. A prize catch for diabetic retinopathy. Nat Med. 2007;13:131-2.
22. Antionetti DA, Barber AJ, Bronson SK, et al. Diabetic retinopathy: Seeing beyond glucose-induced microvascular disease. 2006; 55:2401-11.
23. Xu H, Chen M, Forrester JV. Para-inflammation in the aging retina. Prog Retin Eye Res. 2009;28:348-68.
24. Zheng L, Du Y, Miller C, et al. Critical role of inducible nitric oxide synthase in degeneration of retinal capillaries. Diabetologia. 2007;50(9):1987-96.
25. Kern TS. Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy. Exp Diabetes Res. 2007;2007:95103.
26. Funatsu H, Yamashita H, Noma H, et al. Increased levels of vascular endothelial growth factor and interleukin-6 in the aqueous humor of diabetics with macular edema. Am J Ophthalmol. 2002;133:70-7. (Pubitemid 34076505)
27. Zhang J, Gerhardinger C, Lorenzi M. Early complement activation and decreased levels of glycosylphosphatidylinositolanchored complement inhibitors in human and experimental diabetic retinopathy. Diabetes. 2002;51(12):3499-504. (Pubitemid 35403456)
28. Joussen A, Poulaki V, Le M, et al. A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J. 2004;18 (12):1450-2. (Pubitemid 39561611)
29. Chibber R, Ben-Mahmud AB, Chibber S, et al. Leukocytes in diabetic retinopathy. Curr Diab Rev. 2007;3:3-14. Review. (Pubitemid 46592789)
30. Miyamoto K, Khosrof S, Bursell, et al. Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition. Proc Natl Acad Sci USA. 1999;96:10836-41. (Pubitemid 29442230)
31. Linderkamp O, Ruef P, Zilow EP, et al. Impaired deformability of erythrocytes and neutrophils in children with newly diagnosed insulin-dependent diabetes mellitus. Diabetologia. 1999;42:865-9. (Pubitemid 29325078)
32. Joussen AM, Murata T, Tsujikawa A, et al. Leukocyte-mediated endothelial cell injury and death in the diabetic retina. Am J Pathol. 2001;158(1):147-52. (Pubitemid 32096479)
33. Miller-Lotan R, Miller B, Nakhoul F, et al. Retinal capillary basement membrane thickness in diabetic mice genetically modified at the haptoglobin locus. Diabetes Metab Res Rev. 2007;23:152-6.
34. Tsuchihashi S, Ke B, Kaldas F, et al. Vascular endothelial growth factor antagonist modulates leukocyte trafficking and protects mouse livers against ischemia/reperfusion injury. Am J Pathol. 2006;168:695-705. (Pubitemid 43273480)
35. Klein BE, Knudtson MD. Tsai M, et al. The relation of markers of inflammation and endothelial dysfunction to the prevalence and progression of diabetic retinopathy:Wisconsin epidemiologic study of diabetic retinopathy. Arch Ophthalmol. 2009;127:1175-82.
36. Nguyen TT, Alibrahim E, Islam FM, et al. Inflammatory, hemostatic, and other novel biomarkers for diabetic retinopathy: The multiethnic study of atherosclerosis. Diabetes Care. 2009;32:1704-9.
37. Van Dijk HW, Verbraak FD, Kok PH, et al. Decreased retinal ganglion cell layer thickness in patients with type 1 diabetes. Invest Ophthalmol Vis Sci. 2010;51(7):3660-5.
38. Verma A, Rani PK, Raman R, et al. Is neuronal dysfunction an early sign of diabetic retinopathy? Microperimetry and spectral domain optical coherence tomography (SD-OCT) study in individuals with diabetes, but no diabetic retinopathy. Eye. 2009;23 (9):1824-30.
39. Joussen AM, Murata T, Tsujikawa A, et al. Leukocyte-mediated endothelial cell injury and death in the diabetic retina. Am J Pathol. 2001;158(1):147-52. (Pubitemid 32096479)
40. Bursell SE, Clermont AC, Kinsley BT, et al. Retinal blood flow changes in patients with insulin-dependent diabetes mellitus and no diabetic retinopathy. Invest Ophthalmol Vis Sci. 1996;37 (5):886-97.
41. Curtis TM, Gardiner TA, Stitt AW. Microvascular lesions of diabetic retinopathy: Clues towards understanding pathogenesis? Eye. 2009;23(7):1496-508.
42. Ejaz S, Chekarova I, Ejaz A, et al. Importance of pericytes and mechanisms of pericyte loss during diabetes retinopathy. Diabetes Obes Metab. 2008;10(1):53-63. (Pubitemid 350302431)
43. Caldwell RB, Bartoli M, Behzadian MA, et al. Vascular endothelial growth factor and diabetic retinopathy: Pathophysiological mechanisms and treatment perspectives. Diabetes Metab Res Rev. 2003;19(6):442-55. (Pubitemid 37536961)
44. Alder VA, Su EN, Yu DY, et al. Diabetic retinopathy: Early functional changes. Clin Exp Pharmacol Physiol. 1997;24(9-10):785-8. (Pubitemid 27376246)
45. Linsenmeier RA, Braun RD, McRipley MA, et al. Retinal hypoxia in long-term diabetic cats. Invest Ophthalmol Vis Sci. 1998;39(9):1647-57. (Pubitemid 28361327)
46. Hancock HA, Kraft TW. Oscillatory potential analysis and ERGs of normal and diabetic rats. Invest Ophthalmol Vis Sci. 2004;45 (3):1002-8. (Pubitemid 38868404)
47. Ewing FM, Deary IJ, Strachan MW, et al. Seeing beyond retinopathy in diabetes: Electrophysiological and psychophysical abnormalities and alterations in vision. Endocr Rev. 1998;19 (4):462-76. (Pubitemid 29116016)
48. Jackson GR, Owsley C. Visual dysfunction, neurodegenerative diseases, and aging. Neurol Clin. 2003;21(3):709-28. (Pubitemid 36754063)
49. Park SH, Park JW, Park SJ, et al. Apoptotic death of photoreceptors in the streptozotocin-induced diabetic rat retina. Diabetologia. 2003;46(9):1260-8.
50. Nishimura C, Kuriyama K. Alterations in the retinal dopaminergic neuronal system in rats with streptozotocin-induced diabetes. J Neurochem. 1985;45(2):448-55. (Pubitemid 15233944)
51. Zheng XX, Ng YK, Ling EA. Neuronal and microglial response in the retina of streptozotocin-induced diabetic rats. Vis Neurosci. 2000;17(3):463-71.
52. Dean FM, Arden GB, Dornhorst A. Partial reversal of protan and tritan colour defects with inhaled oxygen in insulin dependent early diabetic subjects. Br J Ophthalmol. 1997;81(1):27-30. (Pubitemid 27068159)
53. Harris A, Arend O, Danis RP, et al. Hyperoxia improves contrast sensitivity in early diabetic retinopathy. Br J Ophthalmol. 1996;80(3):209-13. (Pubitemid 26090347)
54. Feke GT, Buzney SM, Ogasawara H, et al. Retinal circulatory abnormalities in type 1 diabetes. Invest Ophthalmol Vis Sci. 1994;35(7):2968-75. (Pubitemid 24186398)
55. Curtis TM, Gardiner TA, Stitt AW. Microvascular lesions of diabetic retinopathy: Clues towards understanding pathogenesis? Eye. 2009;23:1496-508.
56. Thoumine O, Nerem RM, Girard PR. Changes in organization and composition of the extracellular matrix underlying cultured endothelial cells exposed to laminar steady shear stress. Lab Invest. 1995;73(4):565-76.
57. Stacek Jr JE, Patterson CE, Garcia JG. Protein kinase C phosphorylates caldesmon77 and vimentin and enhances albumin permeability across cultured bovine pulmonary artery endothelial cell monolayers. J Cell Physiol. 1992;153:62-75.
58. Joussen AM. Therapeutic approaches to (diabetic) macular edema. In Joussen AM, Gardner TW, Kirchhof B, Ryan SJ, eds. Retinal Vascular Disease. Heidelberg, Germany: Springer-Verlag, 2007:353-376.
59. Antonetti DA, Barber AJ, Hollinger LA, et al. Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1. A potential mechanism for vascular permeability in diabetic retinopathy and tumors. J Biol Chem. 1999;274:23463-7.
60. Fatt I, Shantinath K. Flow conductivity of retina and its role in retinal adhesion. Exp Eye Res. 1971;12:218-26.
61. Nagelhus EA, Veruki ML, Torp R, et al. Aquaporin-4 water channel protein in the rat retina and optic nerve: Polarized expression in Muller cells and fibrous astrocytes. J Neurosci. 1998;18:2506-19.
62. Doukas J, Hechtinan HB, Shepro D. Endothelial-secreted arachidonic metabolites modulate polymorphonuclear leukocyte chemotaxis and diapedesis in vitro. Blood. 1988;71:771-9.
63. Sears JE, Hoppe G. Triamcinolone acetonide destabilizes VEGF mRNA in Muller Cells under continuous cobalt stimulation. Invest Ophthalmol Vis Sci. 2005;46:4336-41. (Pubitemid 44264640)
64. Gardner TW, Antonetti DA, Barber AJ, et al. Penn State Retina Research Group. Diabetic retinopathy: More than meets the eye. Surv Ophthalmol. 2002;47(suppl):S253-262. (Pubitemid 36351245)
65. Gomez-Ulla F, Marticorena J, Alfaro V, et al. Intravitreal triamcinolone in the treatment for diabetic macular edema. Curr Diabetes Rev. 2006;1:99-112. (Pubitemid 44082953)
66. Wilson CA, Berkowitz BA, Sato Y, et al. Treatment with intravitreal steroid reduces bloodretinal barrier breakdown due to retinal photocoagulation. Arch Ophthalmol. 1992;110:1155-9.
67. Funatsu H, Yamashita H, Ikeda T, et al. Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology. 2003;110:1690-6. (Pubitemid 37025424)
68. Funatsu H, Yamashita H, Sakata K, et al. Vitreous levels of vascular endothelial growth factor and intercellular adhesion molecule 1 are related to diabetic macular edema. Ophthalmology. 2005;112:806-16. (Pubitemid 40631499)
69. Diabetic Retinopathy Clinical Research Network. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology. 2007;114:1860-7.
70. Sonoda Y, Arimura N, Shimura M, et al. Early changes of central macular thickness after intravitreous triamcinolone or bevacizumab in diabetic macular edema or retinal vein occlusion. Retina. 2011;31:290-7.
71. Uckermann O, Kutzera F, Wolf A, et al. The glucocorticoid triamcinolone acetonide inhibits osmotic swelling of retinal glial cells via stimulation of endogenous adenosine signaling. J Pharmacol Exp Ther. 2005;315:1036-45. (Pubitemid 41635389)
72. Wurm A, Iandiev I, Hallborn M, et al. Purinergic receptor activation inhibits osmotic glial cell swelling in the diabetic rat retina. Exp Eye Res. 2008;87:385-93.
73. Paques M, Krivosic V, Girmens JF, et al. Decreased venous tortuosity associated with resolution of macular edema after intravitreal injection of triamcinolone. Retina. 2005;25:1099-101. (Pubitemid 44735114)
74. Powell E, Field R. Diabetic retinopathy in rheumatoid arthritis. Lancet. 1964;2:17-8.
75. Heiss J, Papavassiliou E, Merrill M, et al. Mechanism of dexamethasone suppression of brain tumor-associated vascular permeability in rats. Involvement of the glucocorticoid receptor and vascular permeability factor. J Clin Invest. 1996;98:1400-8. (Pubitemid 26322065)
76. Kuo C-H, Gillies MC. Role of steroids in the treatment of diabetic macular edema. Int Ophthalmol Clin. 2009;2:121-34.
77. Graham RO, Peyman GA. Intravitreal injection of dexamethasone. Treatment of experimentally induced endophthalmitis. Arch Ophthalmol. 1974;92:149-54.
78. Tano Y, Sugita G, Abrams G, et al. Inhibition of intraocular proliferations with intravitreal corticosteroids. Am J Ophthalmol. 1980;89:131-6. (Pubitemid 10160115)
79. McCuen B, Bessler M, Tano Y, et al. The lack of toxicity of intravitreally administered triamcinolone acetonide. Am J Ophthalmol. 1981;91:785-8. (Pubitemid 11078533)
80. Hida T, Chandler D, Arena J, et al. Experimental and clinical observations of the intraocular toxicity of commercial corticosteroid preparations. Am J Ophthalmol. 1986;101:190-5. (Pubitemid 16136575)
81. Wilson C, Berkowitz B, Sato Y, et al. Treatment with intravitreal steroid reduces blood-retinal barrier breakdown due to retinal photocoagulation. Am J Ophthalmol. 1992;110:1155-9.
82. Edelman J, Lutz D, Castro M. Corticosteroids inhibit VEGFinduced vascular leakage in a rabbit model of blood-retinal and blood-aqueous barrier breakdown. Exp Eye Res. 2005;80:249-58.
83. Jermack CM, Dellacroce JT, Heffez J, et al. Triamcinolone acetonide in ocular therapeutics. Surv Ophthalmol. 2007;52:503-22. (Pubitemid 47268546)
84. Penfold P, Gyory J, Hunyor A, et al. Exudative macular degeneration and intravitreal triamcinolone. A pilot study. Aust N Z J Ophthalmol. 1995;23:292-8.
85. Jonas J, Sofker A. Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema. Am J Ophthalmol. 2001;132:425-7. (Pubitemid 32768624)
86. Bonini-Filho MA, Jorge R, Barbosa JC, et al. Intravitreal injection versus sub-tenon's infusion of triamcinolone acetonide for refractory diabetic macular edema: A randomized clinical trial. Invest Ophthalmol Vis Sci. 2005;46:3845-9. (Pubitemid 44264695)
87. Diabetic Retinopathy Clinical Research Network. Randomized trial of peribulbar triamcinolone acetonide with and without focal photocoagulation for mild diabetic macular edema: A pilot study. Ophthalmology. 2007;114:1190-6.
88. Martidis A, Duker JS, Greenberg PB, et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology. 2002;109:920-7. (Pubitemid 34465226)
89. Massin P, Audren F, Haouchine B, et al. Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: Preliminary results of a prospective controlled trial. Ophthalmology. 2004;111:218-24. (Pubitemid 38183217)
90. Jonas JB, Kreissig I, Sofker A, et al. Intravitreal injection of triamcinolone for diffuse macular edema. Arch Ophthalmol. 2003;121:57-61. (Pubitemid 36401766)
91. Gillies MC, Simpson JM, Gaston C, et al. Five-year results of a randomized trial with open-label extension of triamcinolone acetonide for refractory diabetic macula edema. Ophthalmology. 2009;116:2182-7.
92. Ockrim ZK, Sivaprasad S, Falk S, et al. Intravitreal triamcinolone versus laser photocoagulation for persistent diabetic macular oedema. Br J Ophthalmol. 2008;92:795-9. (Pubitemid 351839571)
93. Bressler NM, Edwards A, Beck RW, et al. Exploratory analysis of diabetic retinopathy progression through 3 years in a randomized clinical trial that compares intravitreal triamcinolone acetonide with focal/grid photocoagulation. Arch Ophthalmol. 2009;127 (12):1566-71.
94. Yilmaz T, Weaver CD, Gallagher MJ, et al. Intravitreal triamcinolone acetonide injection for treatment of refractory diabetic macular edema. Ophthalmology. 2009;116:902-13.
95. Gottsfredsdottir MS, Stefansson E, Jonasson F, et al. Retinal vasoconstriction after laser treatment for diabetic macular edema. Am J Ophthalmol. 1993;115:64-7. (Pubitemid 23019040)
96. Figuiira J, Khan J, Nunes S, et al. Prospective randomized controlled trial comparing subthreshold micropulse diode laser photocoagulation and conventional green laser for clinically significant diabetic macular oedema. Br J Ophthalmol. 2009;93(10):1341-4.
97. Gillies MC, McAllister IL, Zhu M, et al. Pretreatment with intravitreal triamcinolone before laser for diabetic macular edema: 6-month results of a randomized, placebo-controlled trial. Invest Ophthalmol Vis Sci. 2010;51(5):2322-8.
98. Steijns D, Duijvesz D, Breedijk MA, et al. Steroid injection in addition to macular laser grid photocoagulation in diabetic macular oedema: A systemic review. Acta Ophthalmol. 2010;88:389-93.
99. Lam DS, Chan CK, Mohamed S, et al. Intravitreal triamcinolone plus sequential grid laser versus triamcinolone or laser alone for treating diabetic macular edema: Six-month outcomes. Ophthalmology. 2007;114:2162-7.
100. Kang SW, Sa HS, Cho HY, et al. Macular grid photocoagulation after intravitreal triamcinolone acetonide for diffuse diabetic macular edema. Arch Ophthalmol. 2006;124:653-8.
101. Larsson J, Zhu M, Sutter F, et al. Relation between reduction of foveal thickness and visual acuity in diabetic macular edema treated with intravitreal triamcinolone. AmJ Ophthalmol. 2005;139:802-6. (Pubitemid 40614764)
102. Mohamed Q, Gillies MC, Wong TY. Management of diabetic retinopathy: A systemic review. JAMA. 2007;298:902-16. (Pubitemid 47311296)
103. Shimura M, Yasuda K, Nakazaya T, et al. Quantifying alterations of macular thickness before and after pan-retinal photocoagulation in patients with severe diabetic retinopathy and good vision. Ophthalmology. 2003;110:2386-94. (Pubitemid 37485170)
104. Mirshahi A, Shenazandi H, Lashay A, et al. Intravitreal triamcinolone as an adjunct to standard laser therapy in coexisting highrisk proliferative diabetic and clinically significant macular edema. Retina. 2010;30:254-9.
105. The Diabetic Retinopathy Clinical Research Network Writing Committee, Googe J, Brucker AJ, Bressler NM, et al. Randomized trial evaluating short-term effects of intravitreal ranibizumab or triamcinolone acetonide on macular edema after focal/grid laser for diabetic macular edema in eyes also receiving panretinal photocoagulation. Retina. 2011;31:1009-27.
106. Song JH, Lee JJ, Lee SJ. Comparison of the short-term effects of intravitreal triamcinolone acetonide and bevacizumab injection for diabetic macular edema. Kor J Ophthalmol. 2011;25(3):156-60.
107. Sohelian M, Ramezani A, Obudi A, et al. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. Ophthalmology. 2009;116:1142-50.
108. Forte R, Cennamo GL, Finelli M, et al. Intravitreal bevacizumab vs intravitreal triamcinolone combined with macular laser grid for diffuse diabetic macular oedema. Eye. 2010;24:1325-30.
109. Synek S, Vojnikovic B. Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular oedema. Coll Antropol. 2010;34 suppl 2:99-103.
110. Kim SJ, Equi R, Bressler NM. Analysis of macular edema after cataract surgery in patients with diabetes using optical coherence tomography. Ophthalmology. 2007;114:881-9. (Pubitemid 46635831)
111. Romero-Aroca P, Fernandez-Ballart J, Almena-Garcia M, et al. Nonproliferative diabetic retinopathy and macular edema progression after phacoemulsification: Prospective study. J Cataract Ref Surg. 2006;32:1438-44. (Pubitemid 44262475)
112. Degenring RF, Vey S, Kamppeter B, et al. Effect of uncomplicated phacoemulsification on the central retina in diabetic and nondiabetic subjects. Graefes Arch Clin Exp Ophthalmol. 2007;245:18-23. (Pubitemid 46766725)
113. Jonas JB, Kreissig I, Budde WM, et al. Cataract surgery combined with intravitreal injection of triamcinolone acetonide. Eur J Ophthalmol. 2005;15:329-35. (Pubitemid 40943929)
114. Lam DS, Chan CK, Mohamed S, et al. Phacoemulsification with intravitreal triamcinolone in patients with cataract and coexisting diabetic macular oedema: A 6-month prospective pilot study. Eye. 2005;19:885-90. (Pubitemid 41195142)
115. Habib MS, Cannon PS, Steel DH. The combination of intravitreal triamcinolone and phacoemulsification surgery in patients with diabetic foveal oedema and cataract. BMC Ophthalmol. 2005;5:15.
116. Akinci A, Muftuoglu O, Altinsoy A, et al. Phacoemulsification with intravitreal bevacizumab and triamcinolone acetonide injection in diabetic patients with clinically significant macular edema and cataract. Retina. 2011;31:755-8.
117. Diabetic Retinopathy Clinical Research Network, Elman MJ, Bressler NM, Qin H, et al. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2011;118:609-14.
118. Thompson JT. Cataract formation and other complications of intravitreal triamcinolone for macular edema. Am J Ophthalmol. 2006;141:629-37.
119. Gillies MC, Kuzniarz M, Craig J, et al. Intravitreal triamcinoloneinduced elevated intraocular pressure is associated with the development of posterior subcapsular cataract. Ophthalmology. 2005;112:139-43. (Pubitemid 40075333)
120. Smithen LM, Ober MD, Maranan L, et al. Intravitreal triamcinolone acetonide and intraocular pressure. Am J Ophthalmol. 2004;138:740-3. (Pubitemid 39452920)
121. Rhee DJ, Peck RD, Belmont J, et al. Intraocular pressure alterations following intravitreal triamcinolone acetonide. Br J Ophthalmol. 2006;90:999-1003. (Pubitemid 44140181)
122. Bae JS, Park SJ, Ham IR, et al. Dose dependent effects of intravitreal triamcinolone acetonide on diffuse diabetic macular edema. Kor J Ophthalmol. 2009;23:80-5.
123. Bhavsar AR, Ip MS, Glassman AR. DRCRnet and the SCORE Study Groups. The risk of endophthalmitis following intravitreal triamcinolone acetonide injection in the DRCRnet and SCORE clinical trials. Am J Ophthalmol. 2007;144:454-6. (Pubitemid 47336932)
124. Moshfeghi DM, Kaiser PK, Bakri SJ, et al. Presumed sterile endophthalmitis following intravitreal triamcinolone acetonide injection. Ophthalmic Surg Lasers Imaging. 2005;36:24-9. (Pubitemid 40128598)
125. Roth DB, Prenner JL, Krajnyk O. Incidence of noninfectious endophthalmitis after intravitreal injection of preservative-free triamcinolone acetonide. Retin Cases Brief Rep. 2008; 2:247-9.
126. Sohn HJ, Han DH, Kim TI, et al. Changes in aqueous concentrations of various cytokines after intravitreal triamcinolone versus bevacizumab for diabetic macular edema. Am J Ophthalmol. 2011;152:686-94.
127. Kwak HW, D'Amico DJ. Evaluation of the retinal toxicity and pharmacokinetics of dexamethasone after intravitreal injection. Arch Ophthalmol. 1992;110(2):259-66.
128. Kupperman BD, Welty D, Robinson MR, et al. Vitreous and systemic pharmacokinetic profiles of intravitreally-administered dexamethasone posterior segment drug delivery system. Presented at: The 26th Annual Meeting of the American Society of Retina Specialists; October 11-15,2008; Wailea,HI.
129. Haller J, Kupperman BD, Blumenkranz MS, et al. Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema. Arch Ophthalmol. 2010;128(3):289-96.
130. Boyer DS, Faba S, Gupta S, et al. Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients. Retina. 2011;31:915-23.
131. Pearson PA, Comstock TL, Ip M, et al. Fluocinolone acetonide intravitreal implant for diabetic macular edema: A 3-year multicenter, randomized, controlled clinical trial. Ophthalmology. 2011;118:1580-7.
132. Campochiaro PA, Brown DM, Pearson A, et al. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology. 2011;118:626-35.
133. Smiddy WE. Economic considerations of macular edema therapies. Ophthalmology. 2011;118:1827-33.